Business context and reporting period
Entity mismatch: The supplied filing is Cerulean Pharma Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2016—not a filing identified as Dare Bioscience, Inc. The filing describes a clinical-stage oncology company developing nanoparticle-drug conjugates, including CRLX101 and CRLX301.
Financial results and liquidity
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| Revenue | $0 in 2016 and 2015 | $0 in 2016 and 2015 |
| Research and development expense | $7.5M vs. $6.7M | $17.3M vs. $11.7M |
| General and administrative expense | $2.8M vs. $2.7M | $5.9M vs. $5.4M |
| Net loss | $10.9M vs. $9.9M | $24.4M vs. $18.3M |
| Basic and diluted loss per share | $(0.40) vs. $(0.37) | $(0.89) vs. $(0.78) |
| Operating cash used | Not presented as a quarterly figure | $24.5M vs. $15.7M |
At June 30, cash and cash equivalents were $47.2M, down from $75.9M at December 31, 2015. Current assets were $48.9M and current liabilities $14.5M. Stockholders’ equity was $25.8M, down from $48.7M. The company reported an accumulated deficit of $185.8M. No operating margin is meaningful because the company had no revenue.
Six-month investing cash use was $0.4M, primarily for equipment; financing cash use was $3.9M, principally loan principal payments. Cash decreased $28.7M during the period. Cash paid for interest was $0.7M.
Debt figures differ within the filing: the balance sheet reports $16.7M of loan payable, while the notes cite $17.1M outstanding under the Hercules agreement and the risk discussion cites approximately $18.6M. The filing text does not provide a clear reconciliation.
Material changes versus the prior comparable period
- Six-month R&D expense increased 48%, led by CRLX101 spending, which rose 45% to $12.1M; CRLX301 spending rose 88% to $3.2M.
- Six-month G&A expense increased 9% to $5.9M. Operating cash use increased 56% to $24.5M, and net loss widened 33% to $24.4M.
- Cash fell from $75.9M at year-end 2015 to $47.2M. Unlike the first half of 2015, the first half of 2016 had no public-offering proceeds or new loan proceeds and included $3.9M of loan repayments.
Outlook, management commentary, risks, and unusual items
- Management estimated that June 30 cash would fund planned operations into Q2 2017, or into Q3 2017 if expenses were reduced or deferred. The company said additional capital would be required for long-term operations; funding availability and terms were uncertain.
- Management expected significant and increasing expenses and operating losses for at least several years. R&D and G&A were expected to rise as trials and development advanced. The filing gave no revenue or earnings guidance.
- CRLX101’s Phase 2 RCC trial had completed enrollment; top-line data were expected in Q3 2016. In July, after quarter-end, the company amended the primary endpoint to independently reviewed progression-free survival. The filing also reported July initiation of the Phase 2 expansion in the paclitaxel ovarian-cancer trial and a second FDA Fast Track designation for that combination.
- CRLX301 had entered its Phase 2a stage in June on an every-three-weeks dosing schedule; a weekly schedule was also under evaluation. The NCI-led CRLX101/olaparib combination trial had dosed its first patient in May.
- Key risks include clinical-trial failure or delays, the prior failure of CRLX101 to meet its overall-survival endpoint in a Phase 2 NSCLC trial, competition and changing standards of care, manufacturing and supply constraints, and dependence on future financing. Hercules debt is secured by substantially all assets other than intellectual property, with restrictive covenants and a July 2018 maturity.
- Calando, a licensor, was in Chapter 7 bankruptcy. The filing said the trustee’s then-current deadline to assume, assign, or reject executory contracts, including the company’s licenses, was August 11, 2016. Potential milestone and royalty obligations to Calando also apply to CRLX101 and CRLX301.
Important facts for investors to verify
- Confirm the issuer identity: this filing is for Cerulean Pharma Inc., not Dare Bioscience, Inc.
- Reconcile the filing’s differing Hercules debt figures and confirm principal, carrying value, payment terms, and covenant status.
- Assess whether the stated cash runway remains realistic against actual spending, trial costs, and the need for additional financing.
- Review the RCC trial’s amended endpoint, the Q3 2016 results, and subsequent clinical updates; the filing’s trial expectations are forward-looking.
- Check the outcome of the Calando bankruptcy deadline and whether the company’s licensed intellectual-property rights were affected.